Selected Grants
A Phase IIb, Randomized, Assessor-Masked, Multicenter Clinical Trial To Assess The Safety And Efficacy Of Subretinal Implantation Of The CPCB-RPE1 Implant In Subjects With Advanced, Dry Age-Related Macular Degeneration (Geographic Atrophy)-PATCH AMD
ResearchPrincipal Investigator · Awarded by Clinical Trials Resource Group, LLC · 2024 - 2031A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
Clinical TrialPrincipal Investigator · Awarded by Priovant Therapeutics, Inc · 2024 - 2029A Phase 1/2a study of subretinal administration of OpCT-001 photoreceptor precursor cells derived from iPSCs in patients with primary photoreceptor disease
ResearchPrincipal Investigator · Awarded by BlueRock Therapeutics LP · 2025 - 2029A MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF THE PROGRESSION OF INTERMEDIATE AGE-RELATED MACULAR DEGENERATION
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2022 - 2027Randomized, double-masked, actiVE-contRolleD, multicenter study to evaluAte efficacy aNd safeTy of two regimens of intravitreal BI 771716 against pegcetacoplan in participants with geographic atrophy secondary to age-related macular degeneration VERD
ResearchPrincipal Investigator · Awarded by Ora LLC · 2024 - 2027A Phase 1/2a, Open-label, Multiple-Cohort, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 in Subjects with Neovascular (wet) Age-Related Macular Degeneration (nAMD).
ResearchPrincipal Investigator · Awarded by Avirmax Biopharma, Inc. · 2024 - 2027JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862_Protocol 1484-0005
ResearchPrincipal Investigator · Awarded by Ora LLC · 2024 - 2027Retinal Light Scattering Measurements as a Clinical Biomarker of Alzheimer's Disease
ResearchCo Investigator · Awarded by National Institute on Aging · 2022 - 2027Whole Eye Optical Coherence Tomography to Improve Eye Care
ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2026A Phase 1, Open-Label, Multiple Ascending Dose Study to Investigate the Safety and Tolerability of Intravitreal Injections of OSA-2-100 in Subjects with Dry Age-Related Macular Degeneration (AMD)
ResearchPrincipal Investigator · Awarded by Osanni Bio, Inc. · 2024 - 2026A Phase 1b, Open-Label, Multiple Ascending Dose Study to Investigate the Safety and Tolerability of OSA-1-100 Intravitreal Implant in Subjects with Dry Age-Related Macular Degeneration (AMD)
ResearchPrincipal Investigator · Awarded by Osanni Bio, Inc. · 2024 - 2025A Proof-of-Concept, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Active Noninfectious Intermediate, Posterior, or Panuveitis (OPTYK-1)
Clinical TrialPrincipal Investigator · Awarded by Alumis Inc. · 2023 - 2025A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active Non-Infectious Intermediate-, Posterior-, and Panuveitis
Clinical TrialPrincipal Investigator · Awarded by Priovant Therapeutics, Inc · 2023 - 2025Automated OCT Technology Translation to Diagnose Traumatic Eye Injury
ResearchCo Investigator · Awarded by United States Army Medical Research Acquisition Activity · 2020 - 2024Regeneron DRC A Double Masked Randomized, Controlled Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema Regeneron VGFT-1009 - Extension
ResearchPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2020 - 2022Novartis DRC Brolucizumab post-marketing imaging project
ResearchPrincipal Investigator · Awarded by Novartis Pharma AG · 2020 - 2022DE-109 LUMINA
Clinical TrialPrincipal Investigator · Awarded by Santen, Ltd. · 2019 - 2021External Relationships
- ANI Pharmaceuticals
- Apellis Pharmaceuticals
- Astellas
- DORC
- EyePoint
- Genentech Roche
- Regeneron Pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.